74420-18-1Relevant articles and documents
Synthesis of 4-Amino-1H-pyrrolopyridine (1,7-Dideazaadenine) and 1H-Pyrrolopyridin-4-ol (1,7-Dideazahypoxanthine)
Schneller, Stewart W.,Luo, Jiann-Kuan
, p. 4045 - 4048 (1980)
4-Amino-1H-pyrrolopyridine (1,7-dideazaadenine) (5) has been synthesized by the iron and acetic acid reduction of 4-nitro-1H-pyrrolopyridine 7-oxide (13), obtained by nitration of 1H-pyrrolopyridine-3-carboxamide 7-oxide (17).Other nitration reactions in the 1H-pyrrolopyridine 7-oxide series are disclosed.The preparation of 1H-pyrrolopyridin-4-ol (1,7-dideazahypoxanthine) (6) began with the hydrolysis of ethyl 1-benzyl-3-cyano-4-oxo-4,7-dihydro-1H-pyrrolopyridine-5-carboxylate (21) to the 3,5-dicarboxylic acid derivative of 1-benzyl-4-oxo-4,7-dihydro-1H-pyrrolopyridine (22).Decarboxylation of 22 with subsequent debenzylation formed 6.
Pyrrolo[3,2-c]pyridine derivatives with potential inhibitory effect against FMS kinase: in vitro biological studies
El-Gamal, Mohammed I.,Oh, Chang-Hyun
, p. 1160 - 1166 (2018/08/12)
A series of eighteen pyrrolo[3,2-c]pyridine derivatives were tested for inhibitory effect against FMS kinase. Compounds 1e and 1r were the most potent among all the other tested analogues (IC50 = 60 nM and 30 nM, respectively). They were 1.6 and 3.2 times, respectively, more potent than our lead compound, KIST101029 (IC50 = 96 nM). Compound 1r was tested over a panel of 40 kinases including FMS, and exerted selectivity against FMS kinase. It was further tested against bone marrow-derived macrophages (BMDM) and its IC50 was 84 nM (2.32-fold more potent than KIST101029 (IC50 = 195 nM)). Compound 1r was also tested for antiproliferative activity against a panel of six ovarian, two prostate, and five breast cancer cell lines, and its IC50 values ranged from 0.15–1.78 μM. It possesses also the merit of selectivity towards cancer cells than normal fibroblasts.
Cell-based biological evaluation of a new bisamide FMS kinase inhibitor possessing pyrrolo[3,2-c]pyridine scaffold
El-Gamal, Mohammed I.,Abdel-Maksoud, Mohammed S.,El-Din, Mahmoud M. Gamal,Yoo, Kyung Ho,Baek, Daejin,Oh, Chang-Hyun
, p. 635 - 641 (2014/11/12)
A bisamide compound 1 possessing the pyrrolo[3,2-c]pyridine nucleus was synthesized and biologically evaluated. It was tested for kinase inhibitory activity over a panel of 47 kinases, and its selectivity toward the FMS kinase was accidentally discovered. Compound 1 was tested over a panel of seven ovarian, two prostate, and six breast cancer cell lines at a single dose concentration of 10μM and showed high activity. It was further tested in a 5-dose mode to determine its IC50 and total growth inhibition (TGI) values over the 15 cell lines. Compound 1 showed high potency on the submicromolar scale and good efficacy. The cytotoxic effect of compound 1 over peritoneal macrophages was also investigated. Compound 1 demonstrated higher selectivity against different cancer cell lines compared with HS-27 fibroblasts.
7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors
Cincinelli, Raffaella,Musso, Loana,Merlini, Lucio,Giannini, Giuseppe,Vesci, Loredana,Milazzo, Ferdinando M.,Carenini, Nives,Perego, Paola,Penco, Sergio,Artali, Roberto,Zunino, Franco,Pisano, Claudio,Dallavalle, Sabrina
, p. 1089 - 1103 (2014/02/14)
7-Azaindole-1-carboxamides were designed as a new class of PARP-1 inhibitors The compounds displayed a variable pattern of target inhibition profile that, in part, paralleled the antiproliferative activity in cell lines characterized by homologous recombination defects A selected compound (1l; ST7710AA1) showed significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp In antitumor activity studies against the MX1 human breast carcinoma growth in nude mice, the compound exhibited an effect similar to that of Olaparib in terms of tumor volume inhibition when used at a lower dose than the reference compound Treatment was well tolerated, as no deaths or significant weight losses were observed among the treated animals
Design and synthesis of an anticancer diarylurea derivative with multiple-kinase inhibitory effect
El-Gamal, Mohammed I.,Oh, Chang-Hyun
scheme or table, p. 1571 - 1576 (2012/07/31)
A diarylurea compound 1 possessing pyrrolo[3,2-c]pyridine nucleus was designed and synthesized with structure similarity to Sorafenib. Compound 1 was tested over 60-cancer cell line panel at a single dose concentration of 10 μM and showed high activity. It was further tested in a five-dose mode to determine its IC50, TGI, and LC50 values over the 60 cell lines. Compound 1 showed high potency and good efficacy, and was accordingly tested at a single dose concentration of 10 μM over a panel of 40 kinases. At this concentration, it completely inhibited the enzymatic activities of a number of oncogenic kinases, including ABL, ALK, c-RAF, FLT3, KDR, and TrkB. The target compound was subsequently tested over these 6 kinases in 10-dose testing mode in order to determine its IC50 values. Copyright
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines
El-Gamal, Mohammed I.,Jung, Myung-Ho,Lee, Woong San,Sim, Taebo,Yoo, Kyung Ho,Oh, Chang-Hyun
scheme or table, p. 3218 - 3226 (2011/07/31)
Synthesis of a new series of diarylureas and diarylamides having 1H-pyrrolo[3,2-c]pyridine scaffold is described. Their in vitro antiproliferative activity against A375P human melanoma cell line was tested and the effect of substituents on pyrrolo[3,2-c]pyridine nucleus was investigated. The newly synthesized compounds, except three N-tolyl derivatives (8f, 9f, and 9h), generally showed superior activity against A375P to Sorafenib. Among all of these derivatives, compounds 8b, 8g, and 9a-e showed the highest potency against A375P with IC50 in nanomolar range. In addition, compounds 8d, 8e, 8h, 9g, 9i, and 9j were more potent than Sorafenib but with IC 50 in micromolar range. Compounds 8b, 8g, 9b-d, and 9i demonstrated higher selectivity towards A375P compared with NIH3T3 fibroblasts. The most potent diarylurea 8g and diarylamide 9d were further tested and showed high potency over nine melanoma cell lines at the NCI.
PYRROLOPYRIDINES AS KINASE INHIBITORS
-
Page/Page column 53, (2009/09/04)
Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Formula, (I).
PHARMACEUTICAL COMPOUNDS
-
Page/Page column 85-86, (2008/06/13)
The invention provides compounds of the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein J1-J2 is CH=CH, N=CH, CH=N, HN-C(O) or CH2CO; T is N or CH and GP is as defined in the claims. The compounds have activity as inhibitors of PKA and PKB kinases and are useful in the treatment of cancers.
Comprehensive studies on dual excitation behavior of double proton versus charge transfer in 4-(N-substituted amino)-1H-pyrrolo[2,3-b]pyridines
Cheng, Chung-Chih,Chang, Chen-Pin,Yu, Wei-Shan,Hung, Fa-Tsai,Liu, Yun-I,Wu, Guo-Ray,Chou, Pi-Tai
, p. 1459 - 1471 (2007/10/03)
Comprehensive spectroscopic and dynamical studies on the dual excitation behavior of proton vs charge transfer for 4-(dimethylamino)-1H-pyrrolo[2,3-b]pyridine (DPP) and its related derivatives are reported. In cyclohexane, DPP dimer and/or dual hydrogen-bonded complex are formed with association constants Ka as high as ～4.2 × 103 and 5.2 × 104 M-1 (e.g., the DPP/acetic acid complex) at 298 K, respectively, which upon electronic excitation undergo ultrafast rate (?6.7 × 1010 s-1) of double-proton transfer, resulting in a unique tautomer emission. Dual fluorescence was observed in polar, aprotic solvents, in which the large Stokes shifted emission band originates from the charge-transfer species incorporating a dimethylamine and pyridine ring as electron donor and acceptor, respectively. Detailed solvent-polarity and temperature-dependent studies in combination with theoretical approaches have been performed to determine the excited-state charge-transfer properties such as dipole moment, orbital configuration, etc. Supplementary support for the dual charge/proton-transfer behavior was provided by the comparative spectroscopy and dynamics of various DPP-related derivatives. Further time-resolved measurements conclude that dual emissions share a common Franck-Condon excited state but undergo two independent relaxation channels. In protic solvents, such as ethanol, following fast solvent relaxation dynamics, the excited charge-transfer state further undergoes a solvent (i.e. alcohol) assisted proton-transfer reaction. The charge versus proton-transfer emission can be distinguished via the temporal spectral evolution. The results demonstrate DPP to be a unique model among 7-azaindole analogues in which the interplay between charge and proton-transfer reactions is operative in the excited state.
